Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Imbalance
Open Access
- 1 July 2009
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (7) , 2269-2276
Abstract
Context: Children with 21-hydroxylase deficiency (21-OHD) need chronic glucocorticoid (cGC) therapy to replace congenital deficit of cortisol synthesis. cGC therapy is the most frequent and severe form of drug-induced osteoporosis, and different mechanisms have been proposed to explain its pathogenesis. Objective: We investigated the osteoclastogenic potential of peripheral blood mononuclear cells (PBMCs) from 18 children with 21-OHD on cGC therapy and 25 controls who never received GCs. We also evaluated the presence of circulating osteoclast precursors (OCPs) and the role of T cells in osteoclast formation. Results: Spontaneous osteoclastogenesis, without adding macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL), and significantly higher osteoclasts resorption activity occurred in 21-OHD patients. Conversely, macrophage-colony stimulating factor and RANKL were essential to trigger and sustain osteoclastogenesis in controls. Furthermore, in 21-OHD patients, we identified a significant percentage of CD11b-CD51/CD61 and CD51/61-RANK-positive cells, which are OCPs strongly committed. Additionally, we demonstrated a T cell-dependent osteoclastogenesis from 21-OHD patients’ PBMCs. T cells from patients expressed high levels of RANKL and low levels of osteoprotegerin (OPG) with respect to controls. Moreover, 21-OHD patients had higher soluble RANKL and lower OPG serum levels compared with controls; thus, soluble RANKL to OPG ratio was significantly higher in patients than controls. Conclusions: The present study showed for the first time a high osteoclastogenic potential of PBMCs from 21-OHD patients on cGC therapy. This spontaneous osteoclastogenesis seems to be supported by both the presence of circulating OCPs and factors released by T cells.Keywords
This publication has 33 references indexed in Scilit:
- Glucocorticoid-induced osteoporosis: pathophysiology and therapyOsteoporosis International, 2007
- Reduced Bone Mineral Density and Increased Bone Metabolism Rate in Young Adult Patients with 21-Hydroxylase DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 2006
- Glucocorticoid-induced osteoporosis: an updateTrends in Endocrinology & Metabolism, 2006
- Long-Term Corticosteroid Replacement and Bone Mineral Density in Adult Women with Classical Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 2006
- Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral densityJournal of Bone and Mineral Metabolism, 2003
- Consensus Statement on 21-Hydroxylase Deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric EndocrinologyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancyEuropean Journal of Endocrinology, 2000
- The Effects of Glucocorticoid Replacement Therapy on Growth, Bone Mineral Density, and Bone Turnover Markers in Children with Congenital Adrenal HyperplasiaThe Journal of Clinical Endocrinology & Metabolism, 1997
- Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21‐hydroxylase deficiencyClinical Endocrinology, 1996
- INCREASED BONE MINERAL DENSITY IN CONGENITAL ADRENAL HYPERPLASIA (CAH)Pediatric Research, 1993